Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare Life Sciences Launches Xuri™ Technology Family

Published: Wednesday, November 13, 2013
Last Updated: Wednesday, November 13, 2013
Bookmark and Share
First product introduced - Xuri Cell Expansion System W25 for the clinical manufacture of cellular immunotherapies.

GE Healthcare Life Sciences has launched Xuri™, a new technology family designed specifically to support and advance the field of cell therapy.

The new technology family, in which the first product is the Xuri Cell Expansion System W25 for the manufacture of cellular immunotherapies in a clinical setting, will combine GE Healthcare’s capabilities in cellular science with the company’s expertise in the development of advanced tools for the manufacture of biopharmaceuticals.

Cell therapy and regenerative medicine, the use of cells to replace damaged tissue or to treat disease, shows great promise for treating many life-threatening and life-limiting illnesses such as cancer, heart disease, Parkinson’s and age-related macular degeneration.

The widespread adoption of these therapies will require the development of robust, scalable manufacturing tools and workflows to generate sufficient, high quality cells for infusion into patients.

With an estimated 2,500 on-going cell therapy and regenerative medicine clinical trials worldwide, many research groups are now looking at how to move from small-scale expansion of cells to a cost-effective, industrialized process.

GE Healthcare’s new Xuri Cell Expansion System W25 is a functionally closed, automated system, specifically designed to be suitable for the requirements of scaling-out cell therapies in a clinical setting.

The system is equipped with dedicated software applications to make it suitable for a regulated manufacturing environment and has been validated for T-cell growth.

The Xuri W25 builds on the GE Healthcare’s WAVE Bioreactor™ technology which is widely used in the development and manufacture of biopharmaceuticals globally.

Eric Roman, General Manager of Research & Applied Markets, GE Healthcare Life Sciences, commented, “Through our scale and innovation, we are committed to addressing the significant challenges that remain in moving from highly promising experimental cell therapies to widely available and affordable treatments. We have an extensive research program, working with leaders in the field such as the Karolinska University Hospital, to develop tailored technologies and workflows. The focus of our Xuri technology family is to enable the safe, reliable and efficient progress of cell therapies from clinical development to commercialization.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Expands Single-Use Manufacturing Capabilities
The expanded site will manufacture a range of single-use products, including cell growth bags, based on a newly developed film platform resulting from GE’s strategic alliance with Sealed Air.
Friday, November 11, 2016
GE Healthcare Life Sciences Strengthens Business Resilience with ISO 22301
$100 million investment to double manufacturing capacity for chromatography media by 2018.
Saturday, December 05, 2015
GE Healthcare Life Sciences and Emerson Team Up
Collaboration will help drive improvements in productivity.
Saturday, November 28, 2015
GE Healthcare Life Sciences to Open Biopharmaceutical Technology and Training Laboratory in Turkey
Supports Turkey’s ambitions to expand domestic biopharmaceutical industry. Laboratory will be a key component of GE’s new Innovation Center in Istanbul.
Friday, November 14, 2014
GE Healthcare Life Sciences Named as Finalist for Four Bioprocess Industry Awards
Awards celebrate and recognize the outstanding people, organizations and technologies.
Saturday, October 04, 2014
GE Healthcare Life Sciences to Create New US Headquarters
When fully operational, the new facility will house more than 500 highly skilled employees and bring more than 220 new jobs to Massachusetts.
Wednesday, August 20, 2014
GE Healthcare Appoints Emmanuel Ligner as General Manager
Emmanuel will oversee all worldwide commercial activities of Company's rapidly growing BioProcess business.
Friday, April 11, 2014
GE Healthcare to Build KUBio Factory for JHL Biotech in China
New factory to give JHL Biotech commercial biopharmaceutical manufacturing capabilities in Asia.
Thursday, September 26, 2013
GE Healthcare Life Sciences and Osaka University Team Up
Top four graduate students to be hosted at GE Healthcare Life Science’s Uppsala site.
Wednesday, August 21, 2013
GE Healthcare Life Sciences Completes Acquisition of Xcellerex, Inc.
Acquisition expands GE Healthcare’s offering of technologies and services for the manufacture of recombinant proteins, antibodies and vaccines.
Tuesday, May 15, 2012
Scientific News
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
More Effective Strategy for Producing Flu Vaccines
Researchers have developed a virus backbone, allowing producers to grow vaccine viruses in mammalian cells, rather than in eggs.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!